ReviewISRN oncology2013
Evolving concepts: how diet and the intestinal microbiome act as modulators of breast malignancy.
Review in ISRN oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Breast cancer and microbiome: a systematic review highlighting challenges for clinical translation.BMC women's health · 2025Pooled it
- Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy.Molecular cancer · 2025Review
- Evaluation of the gut microbiome and sex hormones in postmenopausal women with newly diagnosed hormone receptor-positive breast cancer versus healthy women: a prospective case-control study.Journal of cancer research and clinical oncology · 2025Article
- Unraveling the links between estrogen and gut microbiota in sex-hormone driven cancers.World journal of clinical oncology · 2025Review
- The estrobolome: Estrogen-metabolizing pathways of the gut microbiome and their relation to breast cancer.International journal of cancer · 2025Review
- Characterization of Salivary Microbiota in Japanese Patients with Oral Cancer.International journal of molecular sciences · 2025Article
- The microbiota in breast cancer: dysbiosis, microbial metabolites, and therapeutic implications.American journal of cancer research · 2025Review
- Effects of gut microbiota in breast cancer.Frontiers in oncology · 2025Review
- Diagnosis of non-puerperal mastitis based on "whole tongue" features: non-invasive biomarker mining and diagnostic model construction.Frontiers in cellular and infection microbiology · 2025Article
- Circulating tumor cells clusters and their role in Breast cancer metastasis; a review of literature.Discover oncology · 2024Review
- The Microbiome in the Obesity-Breast Cancer Axis: Diagnostic and Therapeutic Potential.Pathogens (Basel, Switzerland) · 2023Review
- Associations of gut microbiome with endogenous estrogen levels in healthy postmenopausal women.Cancer causes & control : CCC · 2023Article
- A New Paradigm in the Relationship between Gut Microbiota and Breast Cancer: β-glucuronidase Enzyme Identified as Potential Therapeutic Target.Pathogens (Basel, Switzerland) · 2023Review
- Intratumor microbiota: a novel tumor component.Journal of cancer research and clinical oncology · 2023Review
- Review
- How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?International journal of molecular sciences · 2023Review
- Construction of model animals to explore intestinal microbiome for detection of breast cancer.PloS one · 2023Article
- The Prevention of Inflammation and the Maintenance of Iron and Hepcidin Homeostasis in the Gut, Liver, and Brain Pathologies.Journal of Alzheimer's disease : JAD · 2023Review
- Article
- Gut and Breast Microbiota as Endocrine Regulators of Hormone Receptor-positive Breast Cancer Risk and Therapy Response.Endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The intestinal microbiome plays an important role in human physiology. Next-generation sequencing technologies, knockout and gnotobiotic mouse models, fecal transplant data and epidemiologic studies have accelerated our understanding of microbiome abnormalities seen in immune diseases and malignancies. Dysbiosis is the disturbed microbiome ecology secondary to external pressures such as host diseases, medications, diet and genetic conditions often leading to abnormalities of the host immune system. Specifically dysbiosis has been shown to lower circulating lymphocytes, and increase neutrophil to lymphocyte ratio, a finding which has been associated with a decreased survival in women with breast cancers. Dysbiosis also plays a role in the recycling of estrogens via the entero-hepatic circulation, increasing estrogenic potency in the host, which is another leading cause of breast malignancy. Non-modifiable factors such as age and genetic mutations disrupt the microbiome, but modifiable factors such as diet may also lead to profound disruptions as well. A better understanding of dietary factors and how they disrupt the microbiome may lead to beneficial nutritional interventions for breast cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.